onkologie *heute* 04/2023

MET-Alterationen beim nicht-kleinzelligen Lungenkarzinom – Stand der Diagnostik und Therapie (S. 8–15)

F. Länger, N. J. Dickgreber

Literatur:

1. Remon J et al. MET alterations in NSCLC-Current Perspectives and Future Chal-lenges. J Thorac Oncol 2022; S1556-0864(22)01865-2
2. Jørgensen JT, Mollerup J. Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers (Basel) 2022; 14: 2150
3. Paik PK et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skip-ping Mutations. N Engl J Med 2020; 383: 931–43
4. Wolf J et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383: 944–57
5. Recondo G, Che J, Jänne PA, Awad MM. Targeting MET Dysregulation in Cancer. Cancer Discov 2020; 10: 922–34
6. Lee JK et al. Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns. JCO Precis Oncol 2021; 5:PO.21.00122
7. Schildhaus HU et al. MET amplification status in therapy-naïve adeno- and squa-mous cell carcinomas of the lung. Clin Cancer Res 2015; 21: 907–15
8. Guo R et al. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol 2019; 14: 1666–71
9. Camidge DR et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol 2023; 41: 1105–15
10. Fachinformation Tepmetko® (Merck) https://ec.europa.eu/health/documents/community-register/2022/20220216154592/anx_154592_de.pdf / (Zuletzt abgerufen: März 2023)
11. Fachinformation Tabrecta® (Novartis Pharma) (https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_de.pdf. (Zuletzt abgerufen: März 2023)
12. Drilon A et al. Antitumor activity of crizotinib in lung cancers harboring a MET ex-on 14 alteration. Nat Med 2020; 26: 47–51
13. Camidge DR et al. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol 2021; 16: 1017–29
14. Thomas M, Garassino MC, Felip E Tepotinib in patients with MET exon 14 skip-ping NSCLC: primary analysis of the confirmatory VISION cohort C. Presented at: International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria. Abstract OA03.05

15. Scagliotti G et al. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Muta-tion-Positive NSCLC Patients. J Thorac Oncol 2020; 15: 80–90

16. Park K et al. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol 2021; 39: 3391–402

17. Leighl NB et al. 161192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Ann Oncol 2021; 32: S951–S952

18. Cho BC et al. Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study. Ann Oncol 2022; 33: S1085

19. Desai A, Abdayem P, Adjei AA, Planchard D. Antibody-drug conjugates: A prom-ising novel therapeutic approach in lung cancer. Lung Cancer 2022; 163: 96–106

20. Drilon AE et al. A phase 1/2 study of REGN5093 M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC. J Clin Oncol 2022; 40(16_suppl) TPS8593

21. Fernandes M et al. When the MET receptor kicks in to resist targeted therapies. Oncogene 2021; 40: 4061–78

22. Seegobin K et al. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR. Front Oncol 2021; 11:750657

Update zur Immuntherapie beim NSCLC (S. 16–21)

T. Notz, N. Reinmuth, T. Duell

Literatur:

1. Leitlinienprogramm Onkologie. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 2.1, 2022, AWMF-Registernummer: 020/007OL. (https://wwwleitlinienprogramm-onkologiede/leitlinien/lungenkarzinom/). Zugriff am 05.02.2023

2. Reinmuth N et al. Immuntherapie des nichtkleinzelligen Lungenkarzinoms. Der Onkologe 2021; 27: 179–90

3. Reck M et al. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol 2022; 40: 586–97

4. Remon J et al. The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice? J Clin Oncol 2022

5. Reck M et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 2019; 37: 537–46

6. Jassem J et al. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. J Thorac Oncol 2021; 16: 1872–82

7. Gumus M et al. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study. Cancer 2023; 129: 118-129. doi:10.1002/cncr.34477

8. Gandhi L et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 2078–92

9. Socinski MA et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncol 2021; 16: 1909–24

10. Jotte R et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol 2020; 15: 1351–60

11. Spigel D et al. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Annals of Oncology 2019; 30: v851-v934

12. West H et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 924–37

13. Paz-Ares L et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol 2020; 15: 1657–69

14. Paz-Ares L et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198–211

15. Johnson ML et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol 2022

16. Spigel DR et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022; 40: 1301–11

17. Forde PM et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 2018; 378: 1976–86

18. Forde PM et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 2022; 386: 1973–85

19. Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398: 1344–57

20. Martins F et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563–80

21. Postow MA et al. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018; 378: 158–68

22. Akamatsu H et al. Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L). Clin Cancer Res 2022

23. Gobbini E et al. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer 2020; 21: e497-e510

24. Giaj Levra M et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer 2020; 140: 99–106

25. Schoenfeld AJ & Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell 2020; 37: 443–55

26. Sharma P et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 2017; 168: 707–23

27. Besse B et al. HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy Introduction. J Thorac Oncol 2021. OA07.08

Biofaktoren in der komplementären Onkologie: Nicht nur an Vitamin D3 denken (S. 29–33)

D. Birkelbach

Literatur:

1. www.gf-biofaktoren.de

2. www.dge.de/wissenschaft/referenzwerte/vitamin-c/

3. Ma Y et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014; 6(222): 222ra18

4. Parrow NL et al. Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal 2013; 19(17): 2141–56

5. Chen Q et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105(32): 11105–109

6. Chen Q et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102(38): 13604–609

7. Verrax J et al. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009; 47(1): 32–40

8. Creagan ET et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301(13): 687–90

9. Moertel CG et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985; 312(3): 137–41

10. Jacobs C et al. Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review. Oncologist 2015; 20(2): 210–23

11. https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/ (Letzter Zugriff: 02.01.2023)

12. https://www.cancer.gov/research/key-initiatives/ras/ras-central/blog/2020/yun-cantley-vitamin-c (Letzter Zugriff: 02.01.2023)

13. Ohno S et al. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Cancer Res 2009; 29(3): 809–15

14. Nauman G et al. Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants (Basel) 2018; 7(7): 89

15. Mohseni S et al. Effect of vitamins C and E on cancer survival; a systematic review. Daru 2022; 30(2): 427–41

16. Fritz H et al. Intravenous Vitamin C and Cancer: A Systematic Review. Integr Cancer Ther 2014; 13(4): 280–300

17. Bazzan AJ et al. Retrospective Evaluation of Clinical Experience With Intravenous Ascorbic Acid in Patients With Cancer. Cancer Ther 2018; 17(3): 912–20

18. Zasowska-Nowak A et al. High-Dose Vitamin C in Advanced-Stage Cancer Patients. Nutrients 2021; 13(3): 735

19. Sutherland JP et al. Vitamin D Deficiency increases mortality risk in the UK Biobank. Ann Internal Med 2022; 175(11): 1552–59

20. Prasad AS et al. Zinc in cancer prevention. Nutr Cancer 2009; 61(6): 879–87

21. Gelbard A. Zinc in cancer therapy revisited. Isr Med Assoc J 2022; 24(4): 258–62

22. Choi S et al. Selective inhibitory effects of zinc on cell proliferation in esophageal squamous cell carcinoma through Orai1. FASEB J 2018; 32(1): 404–16

23. Kwak JH et al. Dietary zinc intake and mortality in patients with intestinal-type gastric cancer: A prospective cohort study in Korea. Front Oncol 2022; 12: 947405

24. Hoppe C et al. Zinc as a complementary treatment for cancer patients: a systematic review. Clin Exp Med 2021; 21(2): 297–313

Update: Aktuelles zum Endometriumkarzinom (S. 35–40)

E.-M. Grischke

Literatur:

1. World Health Organization (WHO), International Agency for Research on Cancer (2020) Cancer Today - Cancer Incidence and Mortality. (https://gco.iarc.fr/today/home). Zugegriffen am 20.02.23

2. Robert Koch-Institut (RKI) und die Gesellschaft der epide-miologischen Krebsregister in Deutschland e. V. (GEKID)(Hrsg.) (2019) Krebs in Deutschland 20 World Health Organization (WHO), International Agency for Research on Cancer (2020) Cancer Today - Cancer Incidence and Mortality. (https://gco.iarc.fr/today/home). Zugegriffen am 20.02.23

3. Kandoth C et al. Integrated genomic characterization of endometrial carcinoma; Nature 2013; 497: 67–73

4. Galaal K et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2018; 10: CD006655

5. Janda M et al. Effect of Total Laparoscopic Hysterectom vs Total Abdominal Hysterectomy on Disease-Free Survival Among Women with Stage I Endometrial Cancer: A Randomized Clinical Trial. JAMA 2017; 317(12): 1224–33

6. Walker JL et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: GynecologicOncology Group LAP2 Study. J Clin Oncol 2012; 30(7): 695–700

7. Dai Y et al. Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data. Gynecol Oncol 2020; 158(1): 92–8

8. Colombo N et al. (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 27(1): 16–41

9. Colombo N et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer 2016; 26(1): 2–30

10. Wortman BG et al. (2018) Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial Gynecol Oncol 2018; 151: 69–75

11. van den Heerik ASVM et al. PORTEC-4a: international randomized trial of molecularprofile-based adjuvant treatment for women with high intermediate risk endometrial cancer. Int J Gynecol Cancer 2020; 30: 2002–7

12. de Boer SM et al. Adjuvant chemoradiotherapy versus radiotherapy alone for wome with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 295–309

13. Bosse T et al. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results. Eur J Cancer 2014; 50: 2602–10

14. Matei D et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380: 2317–26

15. Salvesen HB et al. Prognostic Significance of Angiogenesis and Ki-67, p53, and p21 Expression: A Population-Based Endometrial Carcinoma Study. J Clin Oncol 1999; 17: 1382

16. Oaknin A et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol 2020; 6: 1766–772

17. Makker V et al. A multicenteropen-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE- 775. Gynecol Oncol SGO2021; #11512

18. Makker V et al. Lenvatinib Plus Pembrolizumab in Patients with Advanced Endometrial Cancer. J Clin Oncol 2020; 38: 2981–92

19. Decruze SB & Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int. J Gynecol Cancer 2007; 17: 964–78

20. Lentz SS et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2996; 14: 357–361

21. Mirza MR et al. LBA28 – A randomized double-blind placebo- controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO/ENGOT-EN3 trial. Ann Oncol 2020; 31: 1142–215